The role of cyclooxygenase-1 and -2 in sevoflurane-induced postconditioning against myocardial infarction

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 3, 2014, Pages 272-280

  Stumpner, Jan ^a   Tischer Zeitz, Tobias ^a   Frank, Anja ^a   Lotz, Christopher ^a   Redel, Andreas ^b   Lange, Markus ^c   Kehl, Franz ^d   Roewer, Norbert ^a   Smul, Thorsten ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Mathias Spital ^*  (Germany)

^d Hospital of Karlsruhe   (Germany)

Author keywords

Cardiac anesthesia; Cyclooxygenase 1; Cyclooxygenase 2; Ischemia reperfusion injury; Postconditioning; Volatile anesthetics

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIMETHYL SULFOXIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; SEVOFLURANE; TRIPHENYLTETRAZOLIUM; ETHER DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CORONARY REPERFUSION; DRUG ANTAGONISM; DRUG POTENTIATION; HEART INFARCTION; HEART INFARCTION SIZE; HEMODYNAMIC PARAMETERS; IN VIVO STUDY; ISCHEMIC POSTCONDITIONING; MALE; NONHUMAN; STATISTICAL ANALYSIS; ANIMAL; C57BL MOUSE; HEMODYNAMICS; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HEMODYNAMICS; ISCHEMIC POSTCONDITIONING; MALE; METHYL ETHERS; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION;

EID: 84922647212     PISSN: 10892532     EISSN: 19405596     Source Type: Journal    
DOI: 10.1177/1089253214523683     Document Type: Article

References (40)

1. Alcindor D, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology. 2004;100:547-554.
2. Lange M, Smul TM, Blomeyer CA, et al. Role of the beta1- Adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. Anesthesiology. 2006;105:503-510.
3. Smul TM, Lange M, Redel A, Burkhard N, Roewer N, Kehl F. Desflurane-induced preconditioning against myocardial infarction is mediated by nitric oxide. Anesthesiology. 2006;105:719-725.
4. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology. 2005;102:102-109.
5. Deyhimy DI, Fleming NW, Brodkin IG, Liu H. Anesthetic preconditioning combined with postconditioning offers no additional benefit over preconditioning or postconditioning alone. Anesth Analg. 2007;105:316-324.
6. Stumpner J, Smul TM, Redel A, et al. Desflurane-induced and ischaemic postconditioning against myocardial infarction are mediated by Pim-1 kinase. Acta Anaesthesiol Scand. 2012;56:904-913.
7. De Hert SG, Van der Linden PJ, Cromheecke S, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology. 2004;101:299-310.
8. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
9. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
10. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081-1091.
11. Bayne K. Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. Physiologist. 1996;39:199, 208-211.
12. Redel A, Jazbutyte V, Smul TM, et al. Impact of ischemia and reperfusion times on myocardial infarct size in mice in vivo. Exp Biol Med (Maywood). 2008;233:84-93.
13. Stumpner J, Redel A, Kellermann A, et al. Differential role of Pim-1 kinase in anesthetic-induced and ischemic preconditioning against myocardial infarction. Anesthesiology. 2009;111:1257-1264.
14. Eckle T, Grenz A, Kohler D, et al. Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol. 2006;291:H2533-H2540.
15. Liao M, Laster MJ, Eger EI, Tang M, Sonner JM. Naloxone does not increase the minimum alveolar anesthetic concentration of sevoflurane in mice. Anesth Analg. 2006;102:1452-1455.
16. Jiang X, Shi E, Nakajima Y, Sato S, Ohno K, Yue H. Cyclooxygenase-1 mediates the final stage of morphineinduced delayed cardioprotection in concert with cyclooxygenase- 2. J Am Coll Cardiol. 2005;45:1707-1715.
17. Chen HT, Yang CX, Li H, et al. Cardioprotection of sevoflurane postconditioning by activating extracellular signalregulated kinase 1/2 in isolated rat hearts. Acta Pharmacol Sin. 2008;29:931-941.
18. Huhn R, Heinen A, Weber NC, Hollmann MW, Schlack W, Preckel B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br J Anaesth. 2008;100:465-471.
19. Preckel B, Schlack W, Comfere T, Obal D, Barthel H, Thamer V. Effects of enflurane, isoflurane, sevoflurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth. 1998;81:905-912.
20. Redel A, Stumpner J, Tischer-Zeitz T, et al. Comparison of isoflurane-, sevoflurane-, and desflurane-induced pre- And postconditioning against myocardial infarction in mice in vivo. Exp Biol Med (Maywood). 2009;234:1186-1191.
21. Guo Y, Bao W, Wu WJ, Shinmura K, Tang XL, Bolli R. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol. 2000;95:479-484.
22. Tanaka K, Ludwig LM, Krolikowski JG, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology. 2004;100:525-531.
23. Penna C, Mancardi D, Tullio F, Pagliaro P. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol. 2008;103:368-377.
24. Tosaka S, Tosaka R, Matsumoto S, Maekawa T, Cho S, Sumikawa K. Roles of cyclooxygenase 2 in sevofluraneand olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts. J Cardiovasc Pharmacol Ther. 2011;16:72-78.
25. Schmelzle M, Felix SB, Staudt A, Herda LR. Cardioprotection of 17, 18-epoxyeicostetraenoic acid in ischemia/reperfusion is mediated by cyclooxygenase-2: A study in a rat model. Transplant Proc. 2011;43:1515-1519.
26. Weber NC, Frassdorf J, Ratajczak C, et al. Xenon induces late cardiac preconditioning in vivo: A role for cyclooxygenase 2? Anesth Analg. 2008;107:1807-1813.
27. Huhn R, Heinen A, Weber NC, et al. Helium-induced late preconditioning in the rat heart in vivo. Br J Anaesth. 2009;102:614-619.
28. Sato H, Bolli R, Rokosh GD, et al. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol. 2007;293:H2557-H2564.
29. Pagel PS. Postconditioning by volatile anesthetics: Salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth. 2008;22:753-765.
30. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460.
31. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol. 2006;38:414-419.
32. Shinmura K, Nagai M, Tamaki K, Tani M, Bolli R. COX-2- derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol. 2002;283:H2534-H2543.
33. Abe T, Hayasaka Y, Zhang XY, Hayasaka S. Effects of intravenous administration of FR122047 (a selective cyclooxygenase 1 inhibitor) and FR188582 (a selective cyclooxygenase 2 inhibitor) on prostaglandin-E2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res. 2004;36:321-326.
34. Goto K, Ochi H, Yasunaga Y, et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat. 1998;56:245-254.
35. Dohi M, Sakata Y, Seki J, et al. The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur J Pharmacol. 1993;243:179-184.
36. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926-13931.
37. Yun Y, Duan WG, Chen P, et al. Down-regulation of cyclooxygenase- 2 is involved in ischemic postconditioning protection against renal ischemia reperfusion injury in rats. Transplant Proc. 2009;41:3585-3589.
38. Feitoza CQ, Goncalves GM, Semedo P, et al. Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med. 2008;14:724-730.
39. Iwasaki W, Kume M, Kudo K, et al. Changes in the fatty acid composition of the liver with the administration of N-3 polyunsaturated fatty acids and the effects on warm ischemia/reperfusion injury in the rat liver. Shock. 2010;33:306-314.
40. Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary collateral circulation during regional myocardial ischaemia: A critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res. 1987;21:737-746.